| __timestamp | Geron Corporation | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 381287000 |
| Thursday, January 1, 2015 | 17793000 | 452612000 |
| Friday, January 1, 2016 | 18761000 | 316800000 |
| Sunday, January 1, 2017 | 19287000 | 330100000 |
| Monday, January 1, 2018 | 18707000 | 265800000 |
| Tuesday, January 1, 2019 | 20893000 | 336200000 |
| Wednesday, January 1, 2020 | 25678000 | 423900000 |
| Friday, January 1, 2021 | 29665000 | 467000000 |
| Saturday, January 1, 2022 | 43628000 | 487000000 |
| Sunday, January 1, 2023 | 69135000 | 477100000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing operational costs is crucial for sustaining growth and innovation. This analysis compares the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and Geron Corporation from 2014 to 2023. Over this period, United Therapeutics consistently outspent Geron, with SG&A expenses peaking at approximately $487 million in 2022, a 28% increase from 2014. In contrast, Geron's expenses grew more modestly, reaching around $69 million in 2023, marking a significant 312% rise from its 2014 figures. This disparity highlights United Therapeutics' expansive operational scale compared to Geron. The data underscores the strategic financial management required in the biotech sector, where balancing cost with innovation can dictate market leadership. As these companies navigate the evolving landscape, their SG&A trends offer insights into their strategic priorities and market positioning.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.